Stockreport

AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headac...

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF Pivotal Phase 3 ECLIPSE study demonstrated atogepant is superior to placebo for achieving pain freedom at two hours after treatment of the first migraine attack (24.3% f [Read more]